Michel Orsinger, CEO of Synthes, recently received $52 million as a result of Johnson & Johnson's acquisition of the company, if the deal closes sometime over the next two years, according to a Philadelphia Inquirer report.
The Latest
Pain management is a specialty in flux. Not only are more chronic pain sufferers seeking out treatment, but the release of a recent Center for Disease Control report, which found more people die from prescription drug overdoses than heroin and…
Here are 15 orthopedic surgeons who recently joined practice groups.
The Longstreet Clinic in Gainesville, Ga., recently opened the new Orthopaedics & Sports Medicine office in Buford, Ga., according to a Longstreet Clinic news release.
The Kentucky Spinal Cord Injury Research Center at the University of Louisville researchers received more than $13.7 million in extramural funding over the past year, according to a University of Louisville Today news report.
Lawrence Dorr, MD, founder of the Dorr Arthritis Institute at Good Samaritan Hospital in Los Angeles, recently published a novel titled Die Once, Live Twice, detailing the history of medicine, according to a story from Authorlink.
A research group, led by researchers at the Cleveland Clinic, found a one-time injection of fibronectin immediately after spinal cord injury can limit pain for up to eight months, according to a news release.
Decision Resources, a pharmaceutical and healthcare research and advisory firm, found therapies to treat chronic back pain and arthritis pain will continue to be the most profitable segments of the chronic pain drug market through 2020, according to a news…
The Oxford Partial Knee System from Biomet, a fully mobile-bearing partial knee replacement system, recently celebrated its 35th anniversary. The system is cleared by the FDA and has shown a 91 percent success rate in independent studies. Keith Berend, MD,…
A recent study published in Spine showed that the formation of anti-BMP-2 antibodies is low and transient in spinal fusion patients, and the formation of antibodies doesn't affect fusion rates or have clinical sequelae.